Purchasing a pipeline – perils, pitfalls, and priorities in asset acquisition
Checkpoint inhibitors. Genetic therapies. Biomarker therapies. To hear big pharma tell it, we are living in an age of medical wonders.
The problem? In some patients, they make a huge difference. In others, they don’t work at all.
From a bench-science standpoint, that’s fascinating. But if you’re a pharmaceutical executive thinking seriously about pipeline asset acquisition, translating large-molecule science into high-profit marketability is fraught with complexity.
In this White Paper, we will look at new and changing trends in pipeline acquisition, discuss difficulties inherent in the current marketplace, and offer worthwhile perspectives on pitfalls and opportunities based on our experience offering strategic guidance to pharmaceutical companies on a global scale.
Big pharma pipelines are not what they used to be
The majority of new drugs measure their success in increments.
Orphan drugs and tightly targeted MOAs offer the most exciting breakthroughs, but they offer them to smaller and smaller groups of patients. New cancer drugs are launched with great fanfare even when their pivotal studies suggest they offer a scant three months’ improvement over the competition. Small molecules are languishing. Biologics, once heralded as an arena of unbounded promise, are nearing the end of their patent lives, negotiating payments worth millions to keep biosimilars off the market.
You may also be interested in…
Maximise product value through Medical Insights
Medical Insights is emerging as a transformative organisational capability within Medical Affairs that aims to capture real-world insights through medical channels and use them to maximise product and portfolio value.
Deallus sponsoring and speaking at the Pharma CI EU Conference
We are excited to be sponsoring and speaking at the Pharma CI EU conference, held in Rome on 30-31 March 2023. Julie Munch Khan, COO, and Stephen Small, Senior Principal at Deallus will be joining other Competitive Intelligence experts across Pharma, Biotech and Medical Devices.
Overview of current policy for rare disease in China
For the first time after decades of negligence in this area, China published the First List of Rare Diseases (FLRDs). This was a key step in improving and standardising the regulatory system of rare disease management, orphan drug development, and review and approval.
HIV/AIDS
Human immunodeficiency virus (HIV) is the virus that is responsible for Acquired Immune Deficiency Syndrome (AIDS). HIV continues to be a major global public health issue having claimed the lives of 36.3 million people so far, according to World Health Organization (WHO).